How Can Broadening Our Knowledge in Bioconjugate Design & Development Help Develop Better Medicines?

Antibody-drug conjugates (ADCs) are at the forefront of targeted cancer therapy. They combine the precision of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs to destroy cancer cells, without harming healthy tissue.

In a recent interview with Xtalks, Dr. Petra Dieterich, Senior Vice President and Scientific Leader at Abzena, shared her comprehensive insights into the sophisticated world of ADCs and their evolving role in cancer treatment. The conversation with Dr. Dieterich highlighted the dynamic nature of this field. ADCs have emerged as powerful tools in the fight against cancer. Despite their transformative potential, several challenges must be overcome to maximize their therapeutic efficacy and safety. As the field continues to evolve, the prospects of ADCs are also expanding, promising more targeted and effective treatments across a broader range of diseases.